All In Biotech

Drug Trial Radar · NCT00271583

Efficacy Trial of CDB 2914 for Emergency Contraception

A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception

Last checked: Nov 20, 2026Latest source record: Dec 17, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,672 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,672

Actual

Start

Sep 1999

Primary completion

Not stated

Study completion Sep 2001

Sponsor

Lead sponsor
University of PittsburghAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Jan 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Objective: To compare the efficacy, safety and tolerance of a 50 mg dose of a new antiprogestin, CDB-2914 with a 0.75 mg bid dose of levonorgestrel as emergency contraception Design: Multicenter, randomized, double blind Phase II study to compare a 50 mg dose of CDB-2914 to a 0.75 mg bid dose of levonorgestrel as emergency contraception Subjects are randomized to receive a one-time treatment with either one dose of 50 mg CDB-2914 (followed 12 hours later by a placebo) or 2 doses of 0.75 mg of levonorgestrel with follow-up visits at 5-7 days after expected onset of menses and another visit at 12-14 days after expected onset of menses (if needed) The primary aim is to evaluate the efficacy of CDB-2914 used by subjects as an emergency postcoital contraceptive in comparison to a group of subjects receiving levonorgestrel.

Conditions

  • Emergency Contraception

Interventions

  • CDB-2914Drug

  • levonorgestrelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy (efficacy)Time frame: until follow-up about one week after next menses

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • California Family Health Council

    Los Angeles, California

  • University of Colorado

    Denver, Colorado

  • New York University

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Eastern Virginia Medical School

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.